- Race Oncology (RAC) launches a new collaborative research project to uncover how its Zantrene product protects the heart from chemotherapy-induced damage
- The company has teamed up with the University of North Carolina in the US for the project, led by cardiologist-scientist Brian Jensen
- The collaboration will use state-of-the-art biochemical, cellular and mouse models of cardioprotection to will help with the future selection of optimal dosing in clinics
- The project is expected to take 12 months, with a budgeted cost of US$101,261 (A$150,000)
- Race Oncology is up 5.58 per cent, trading at $2.27 at 3:46 pm AEDT
Race Oncology (RAC) has launched a new collaborative research project to uncover how Zantrene protects the heart from chemotherapy-induced damage.
The company has teamed up with the University of North Carolina at Chapel Hill, USA, for the project, led by cardiologist-scientist and cardio-oncology key opinion leader Brian Jensen.
“Race is extremely pleased to be working with Dr Jensen and his world-leading cardio-oncology research group,” Race Chief Scientific Officer Daniel Tillett said.
“Discovering how Zantrene protects the heart from the highly effective, but cardiotoxic, drugs like doxorubicin is critical for our aims of using its cardioprotective effects in the clinic,” Dr Tillet said.
Race said understanding the molecular mechanisms of how Zantrene could mitigate the cardiotoxicity of the current standard-of-care chemotherapies would help with the future selection of optimal dosing in the clinic.
The collaboration will use state-of-the-art biochemical, cellular and mouse models of cardioprotection.
The company previously reported Zantrene could protect human heart muscle cells from anthracycline-induced cell death. It also can synergise with anthracyclines to better kill breast cancer cells, making it the first reported chemotherapeutic agent to show both anticancer and cardioprotective effects.
“The preclinical discovery that Zantrene in combination with chemotherapy can protect the heart while better-treating cancer has the potential to significantly change standard-of-care cancer treatment and have a meaningful impact on the lives of patients,” Race CEO Damian Clarke-Bruce said.
The project is expected to take 12 months, with a budgeted cost of US$101,261 (A$150,000).
Race Oncology shares were up 5.58 per cent and trading at $2.27 at 3:46 pm AEDT.